Therapeutic Approach to Alzheimer’s Disease: Current Treatments and New Perspectives
Metadatos
Afficher la notice complèteAuteur
Pardo Moreno, Teresa; Gónzalez Acedo, Anabel; Rivas Domínguez, Antonio; García-Morales, Victoria; García-Cozar, Francisco Jose; Ramos Rodríguez, Juan José; Melguizo-Rodríguez, LucíaEditorial
MDPI
Materia
Alzheimer’s disease dementia A pathology
Date
2022-05-24Referencia bibliográfica
Pardo Moreno, T. et. al. Pharmaceutics 2022, 14, 1117. [https://doi.org/10.3390/pharmaceutics14061117]
Patrocinador
P20-01293 from Junta de Andalucía, Spain, PECART-0096- 2020 from Junta de Andalucía, Spain; PID2020-117544RB-100 from the Ministry of Science and Innovation, SpainRésumé
Alzheimer’s disease (AD) is the most common cause of dementia. The pathophysiology of
this disease is characterized by the accumulation of amyloid- , leading to the formation of senile
plaques, and by the intracellular presence of neurofibrillary tangles based on hyperphosphorylated
tau protein. In the therapeutic approach to AD, we can identify three important fronts: the approved
drugs currently available for the treatment of the disease, which include aducanumab, donepezil,
galantamine, rivastigmine, memantine, and a combination of memantine and donepezil; therapies
under investigation that work mainly on A pathology and tau pathology, and which include
-secretase inhibitors, -secretase inhibitors, -secretase modulators, aggregation inhibitors, metal
interfering drugs, drugs that enhance A clearance, inhibitors of tau protein hyperphosphorylation,
tau protein aggregation inhibitors, and drugs that promote the clearance of tau, and finally, other
alternative therapies designed to improve lifestyle, thus contributing to the prevention of the disease.
Therefore, the aim of this review was to analyze and describe current treatments and possible future
alternatives in the therapeutic approach to AD.